A couple of hit pieces out after ASCO conference. Most concern the small sample group and lack of a control group. Yet BMS and Nektar are proceeding into a Phase III trial.

This is a good article on the preliminary results coming out of ASCO 2018.

https://www.forbes.com/sites/matthewherper/20...86c24445b6

I wouldn't try to catch the falling knife today. Let the stock settle and then make your bet.